PTK7 and breast cancer: Low‐dose administration of the PTK7‐targeting MedTAC (MedTACPTK7) resulted in a sustained reduction of PTK7 in breast cancer‐bearing mice, maintaining a 44% degradation rate three days post‐treatment, without significant systemic toxicity.